Results 261 to 270 of about 75,068 (344)

Differential mTORC1 pathways in BHD [PDF]

Nature Reviews Urology, 2020
openaire   +3 more sources

Blockade of cannabinoid CB1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

British Journal of Pharmacology, EarlyView.
Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid CB1 receptor is a potential therapeutic target.
Océane Pointeau, Awa Isma Ba, Audrey Geissler, Romain Barbosa, Abhishek Basu, Arif Muhammad, Marina Nivot, Maéva Loriot, Julia Leemput, Patricia Passilly‐Degrace, Sébastien Causse, Laurent Demizieux, Hélène François, Bruno Vergès, Jianmin Duan, Geneviève Gaucher, Michael Harvey, Pascal Degrace, Glenn Crater, Resat Cinar, Tony Jourdan   +20 more
wiley   +1 more source

Ras homolog enriched in brain 1 regulates β cell mass and β cell function <i>via</i> mTORC1/AMPK/Notch1 pathways. [PDF]

World J Diabetes
Yang Y, Song WJ, Zhang JJ.
europepmc   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

MTORC1 Inhibition Increases Neurotensin Secretion and Gene Expression Through Activation of MEK/ERK/C-Jun Pathway in the Human Endocrine Cell Line BON

, 2011
Jing Li, Jianyu Liu, Jun Song, Heidi L. Weiss, Courtney M. Townsend, Tianyan Gao, B.M. Evers   +6 more
openalex   +1 more source

Machine Learning‐Based Predictive Modeling Maximizes the Efficacy of mTOR/p53 Co‐Targeting Therapy Against AML

Cancer Science, EarlyView.
Although mTOR inhibitors show limited clinical efficacy against AML, this study demonstrates that combining mTOR inhibition with TP53 activation enhances anti‐leukemic effects. We also developed a gene scoring system (Rapa‐11) predicting rapamycin sensitivity and showed that monocytic AMLs with wild‐type TP53 and low Rapa‐11 scores are highly ...
Jingmei Li, Emi Sugimoto, Keita Yamamoto, Yutong Dai, Wenyu Zhang, Yu‐Hsuan Chang, Jakushin Nakahara, Tomohiro Yabushita, Toshio Kitamura, Sung‐Joon Park, Kenta Nakai, Susumu Goyama   +11 more
wiley   +1 more source

Structural insights into cholesterol sensing by the LYCHOS-mTORC1 pathway. [PDF]

Nat Commun
Yu S, Ding JH, Wang JL, Wang W, Zuo P, Yang A, Dai Z, Yin Y, Sun JP, Liang L.   +9 more
europepmc   +1 more source

Faculty Opinions recommendation of Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication.

, 2011
Utpal Banerjee, Kevin T. Jones
openalex   +2 more sources

Molecular logic of mTORC1 signalling as a metabolic rheostat

Nature Metabolism, 2019
Alexander J. Valvezan, B. Manning
semanticscholar   +1 more source

Genome‐Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours

Cell Proliferation, EarlyView.
To identify genetic events that can lead to tumour death once either MLH1 or TP53 is mutated, a genome‐wide genetic screening was performed, uncovering a list of putative hits. Synthetic lethal interactions were validated either genetically or chemically by using small molecules that inhibit these genes either in vitro and in vivo.
Rivki Cashman, Guy Haim‐Abadi, Elyad Lezmi, Hagit Philip, Jonathan Nissenbaum, Ruth Viner‐Breuer, Chen Kozulin, Tamar Golan‐Lev, Aseel Gadban, Shiri Spinner‐Potesky, Ofra Yanuka, Oded Kopper, Nissim Benvenisty   +12 more
wiley   +1 more source